Details

Autor(en) / Beteiligte

• Ihongbe, Timothy O.
• Kim, Jae-Eun C.
• Dahlen, Heather
• Kranzler, Elissa C.
• Seserman, Kate
• Moffett, Kenneth
• Hoffman, Leah

Titel

Trends in primary, booster, and updated COVID-19 vaccine readiness in the United States, January 2021–April 2023: Implications for 2023–2024 updated COVID-19 vaccines

Ist Teil von

• Preventive medicine, 2024-03, Vol.180, p.107887-107887, Article 107887

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• COVID-19 vaccines have mitigated the severity of COVID-19 and its sequelae. The emergence of new SARS-CoV-2 variants and waning immunity conferred by COVID-19 vaccination have necessitated booster and updated COVID-19 vaccines. This study examined trends in vaccine readiness—a composite measure of intention and uptake—for the primary, booster, and 2022–2023 updated (bivalent) COVID-19 vaccines among U.S. adults. Data from the nationally-representative U.S. Department of Health and Human Services' COVID-19 Monthly Outcome Survey from January 2021 to April 2023 were analyzed (N = 140,180). We conducted pairwise comparisons (weighted t-tests) to assess for significant between-month differences in the proportion of participants in each vaccine-readiness category (vaccine ready, wait and see, and no vaccine intention) for the following outcomes: (1) primary; (2) booster; and (3) updated COVID-19 vaccine readiness. From January 2021 to April 2023, significant increases in the primary vaccine ready group were accompanied by decreases in the wait and see and no vaccine intention groups (p < 0.001). From January to September 2022, the no booster intention group notably increased (p < 0.001), whereas the booster ready group decreased (p < 0.001), and the wait and see group remained stable (p = 0.116). From October 2022 to April 2023, the no updated vaccine intention group increased (p < 0.001), the wait and see group decreased (p < 0.01), and the updated vaccine ready group remained unchanged (p = 0.357). Findings show decreased vaccine readiness for the booster and 2022–2023 updated (bivalent) COVID-19 vaccines relative to the primary COVID-19 vaccines. Implications for the 2023–2024 updated COVID-19 vaccines are discussed. •Substantial increase in vaccine readiness for the primary COVID-19 vaccine series.•Steady decline in vaccine readiness for the COVID-19 booster vaccines.•Decreased vaccine readiness for the 2022–2023 updated (bivalent) COVID-19 vaccines.